How semaglutide works: the GLP-1 science explained
One gut hormone, one engineered molecule. The mechanism behind semaglutide's results — appetite, gastric emptying, glucose control — plus oral vs injectable.
The incretin system, briefly
After you eat, your gut releases hormones called incretins that tell the pancreas to release insulin. The most important is GLP-1, which slows stomach emptying so you feel full longer, acts on appetite centers in the brain to reduce hunger, and boosts glucose-dependent insulin secretion. Natural GLP-1 is broken down within minutes; semaglutide is engineered to resist that breakdown and act for days.
What semaglutide does at the receptor
Semaglutide binds and activates the GLP-1 receptor, amplifying all three effects of the natural hormone. The appetite and gastric-emptying effects are what patients notice most: meals feel satisfying sooner, hunger falls, and total caloric intake drops. Over months this produces the weight loss quantified in STEP 1 (~14.9%) and sustained in STEP 5 (~15.2% at two years).
Why the same mechanism helps blood sugar and weight
One elegant feature of GLP-1 biology is that a single mechanism addresses two problems at once, which is why semaglutide exists in both a diabetes form (Ozempic) and a weight form (Wegovy) at different doses. The glucose-dependent nature of its insulin effect is crucial: semaglutide enhances insulin release only when blood sugar is elevated, and suppresses glucagon. Because the insulin effect switches off as glucose normalizes, semaglutide alone carries a low risk of hypoglycemia. The weight and glucose effects share the same receptor activity but express through different tissues — pancreas, gut, and brain — which is why benefits extend to blood pressure, lipids, and inflammation, and ultimately to the cardiovascular event reduction seen in SELECT.
Why it's a once-weekly injection
Natural GLP-1 lasts minutes. Semaglutide is engineered with a fatty-acid chain that binds albumin in the blood, extending its half-life to about a week — long enough for stable once-weekly dosing. That design underpins the slow titration schedule, which governs both efficacy and tolerability, and on dose-tiered plans, your monthly bill. Nothing about semaglutide's behavior is arbitrary once you see the biology underneath it.
Oral vs injectable: same molecule, different delivery
Semaglutide exists in both injectable and oral forms, and the difference illuminates the biology. The injectable is absorbed steadily thanks to the albumin-binding design. The oral form (Rybelsus) faces a harder problem: peptides are normally destroyed by stomach acid and absorbed poorly, so it uses an absorption enhancer that creates a small uptake window — which is why it must be taken on an empty stomach with minimal water and a waiting period before eating. Only a small fraction of an oral dose reaches the bloodstream, so oral doses are much larger in milligrams. For weight management, the injectable 2.4 mg dose has the strongest evidence base. In the compounded market, injectable semaglutide dominates because the vial-and-syringe format is straightforward to compound. The mechanism is identical either way; the delivery route shapes dosing, timing, and which evidence applies.
Frequently asked questions
How does semaglutide work?
Semaglutide is a GLP-1 receptor agonist that mimics the gut hormone GLP-1. It slows gastric emptying, reduces appetite via brain signaling, and enhances glucose-dependent insulin release, together reducing food intake and producing weight loss.
Why does semaglutide reduce appetite?
By activating GLP-1 receptors in appetite-regulating brain regions and slowing stomach emptying, semaglutide makes meals feel satisfying sooner and reduces hunger, lowering caloric intake.
Is semaglutide the same as Ozempic and Wegovy?
Semaglutide is the active ingredient in both Ozempic (type 2 diabetes) and Wegovy (weight management). Compounded semaglutide contains the same molecule but is not FDA-approved.
Why is semaglutide injected only once a week?
It's engineered with a fatty-acid chain that binds albumin, extending its half-life to about a week, allowing stable once-weekly dosing.
Why the biology explains every practical rule
Once you understand the mechanism, the practical rules of semaglutide stop feeling arbitrary and start following logically from the biology. The once-weekly schedule follows directly from the albumin-binding half-life of about a week. The slow titration schedule follows from the fact that the gut effects driving nausea are strongest when the dose changes, not when it is high and stable. The weight regain after stopping follows from the simple fact that the appetite-suppressing signal disappears once the drug clears the body, so the biological drive to eat returns to its pre-treatment set point. The low hypoglycemia risk follows from the glucose-dependence of the insulin effect. Even the cardiovascular benefit seen in SELECT has a mechanistic thread: GLP-1 receptors are present in the heart and blood vessels, and the anti-inflammatory and blood-pressure effects appear to contribute beyond weight loss alone. For a patient, this coherence is reassuring and useful: it means the guidance a good provider gives is not a set of disconnected rules to memorize but a single mechanism expressed in different ways. It also means that shortcuts which fight the biology — escalating too fast to reach results sooner, or stopping abruptly once a goal is hit — tend to backfire in predictable ways. Working with the mechanism rather than against it is the throughline of successful treatment.
References
- Wilding JPH, et al. STEP 1. N Engl J Med. 2021.
- Novo Nordisk. Wegovy Prescribing Information — clinical pharmacology.
- Lincoff AM, et al. Semaglutide and cardiovascular outcomes (SELECT). N Engl J Med. 2023.
- RxCompareHub science journal, July 2026.
Clinical figures from published trials and FDA labeling; pricing from provider-advertised rates checked July 2026 and subject to change. Educational, not medical or financial advice.